Amgen Inc. $AMGN Position Lessened by Novem Group

Novem Group reduced its position in Amgen Inc. (NASDAQ:AMGN) by 72.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 4,128 shares of the medical research company’s stock after selling 10,773 shares during the quarter. Novem Group’s holdings in Amgen were worth $1,740,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Rational Advisors Inc. increased its holdings in Amgen by 13.7% in the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock valued at $72,000 after buying an additional 24 shares in the last quarter. Beacon Financial Advisory LLC raised its position in shares of Amgen by 2.0% in the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after acquiring an additional 25 shares during the period. James T. Borello RIA boosted its stake in shares of Amgen by 13.6% during the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock worth $88,000 after acquiring an additional 25 shares in the last quarter. Sweeney & Michel LLC boosted its stake in shares of Amgen by 0.5% during the 3rd quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock worth $2,162,000 after acquiring an additional 25 shares in the last quarter. Finally, Legacy Financial Advisors Inc. grew its position in shares of Amgen by 0.8% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after acquiring an additional 26 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AMGN. UBS Group lifted their price target on Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a research note on Friday, October 9th. Scotiabank increased their price target on Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a research report on Monday, September 28th. Piper Sandler increased their price target on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. HSBC lowered Amgen from a “buy” rating to a “hold” rating and dropped their price objective for the company from $445.00 to $425.00 in a report on Thursday, September 10th. Finally, Sanford C. Bernstein boosted their price objective on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Amgen has an average rating of “Hold” and a consensus target price of $387.93.

Amgen Price Performance

NASDAQ:AMGN traded down $7.55 during trading hours on Monday, reaching $424.94. 2,681,575 shares of the company were exchanged, compared to its average volume of 2,758,142. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm has a market cap of $229.74 billion, a PE ratio of 26.41, a price-to-earnings-growth ratio of 3.17 and a beta of 0.41. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $447.03. The stock’s 50-day moving average is $415.69 and its 200-day moving average is $375.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same quarter last year, the business earned $6.02 earnings per share. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date was Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Insider Transactions at Amgen

In related news, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 over the last ninety days. 0.85% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Australia’s Pharmaceutical Benefits Advisory Committee conditionally backed coverage for Imdelltra, Amgen’s treatment for small-cell lung cancer. A reimbursement decision could improve patient access and support future sales, although the conditional nature leaves implementation and approval details unresolved. PBAC conditionally backs Imdelltra
• Positive Sentiment: Exchange-traded funds reportedly purchased approximately $19.4 million of Amgen shares on October 15, indicating institutional demand and potentially providing technical support. Such flows are supportive but do not change the company’s underlying earnings outlook. ETFs Bought $19.4 Million of Amgen
• Neutral Sentiment: Several reports highlight Amgen’s broad portfolio, dividend, and potential growth from newer therapies. Zacks coverage mainly reflects increased investor attention rather than a new operational catalyst or change in estimates. Amgen: The Biotech Pioneer Preparing for Its Next Growth Wave
• Negative Sentiment: Analysts and market commentary emphasize that Amgen now needs stronger growth to justify its valuation. Mature products generate dependable cash flow and support the dividend, but investors are looking for faster expansion from newer drugs, making pipeline execution and commercial uptake key risks. Amgen Has the Drugs and the Dividend

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.